Follow
Yvonne Y Li
Yvonne Y Li
Dana Farber cancer Institute
Verified email at bcgsc.ca
Title
Cited by
Cited by
Year
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ...
Nature communications 7 (1), 1-9, 2016
11542016
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor MicroenvironmentImmunosuppressive …
S Koyama, EA Akbay, YY Li, AR Aref, F Skoulidis, GS Herter-Sprie, ...
Cancer research 76 (5), 999-1008, 2016
4082016
Mechanisms and therapeutic implications of hypermutation in gliomas
M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ...
Nature 580 (7804), 517-523, 2020
2812020
Drug repositioning for personalized medicine
YY Li, SJM Jones
Genome medicine 4 (3), 1-14, 2012
2652012
Genomic Analysis of Metastatic Cutaneous Squamous Cell CarcinomaGenomics of Metastatic Cutaneous Squamous Carcinomas
YY Li, GJ Hanna, AC Laga, RI Haddad, JH Lorch, PS Hammerman
Clinical cancer research 21 (6), 1447-1456, 2015
2402015
Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations
YY Li, GTY Chung, VWY Lui, KF To, BBY Ma, C Chow, JK Woo, KY Yip, ...
Nature communications 8 (1), 1-10, 2017
2352017
LKB1 loss links serine metabolism to DNA methylation and tumorigenesis
F Kottakis, BN Nicolay, A Roumane, R Karnik, H Gu, JM Nagle, ...
Nature 539 (7629), 390-395, 2016
2222016
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
SJM Jones, J Laskin, YY Li, OL Griffith, J An, M Bilenky, YS Butterfield, ...
Genome biology 11 (8), 1-12, 2010
1882010
Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells
AL Stratford, CJ Fry, C Desilets, AH Davies, YY Cho, Y Li, Z Dong, ...
Breast Cancer Research 10 (6), 1-12, 2008
1542008
cisRED: a database system for genome-scale computational discovery of regulatory elements
G Robertson, M Bilenky, K Lin, A He, W Yuen, M Dagpinar, R Varhol, ...
Nucleic acids research 34 (suppl_1), D68-D73, 2006
1322006
Stemness-related markers in cancer
W Zhao, Y Li, X Zhang
Cancer translational medicine 3 (3), 87, 2017
1292017
Improving the specificity of high-throughput ortholog prediction
DL Fulton, YY Li, MR Laird, BGS Horsman, FM Roche, FSL Brinkman
BMC bioinformatics 7 (1), 1-16, 2006
1272006
A computational approach to finding novel targets for existing drugs
YY Li, J An, SJM Jones
PLoS computational biology 7 (9), e1002139, 2011
1262011
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
GS Herter-Sprie, S Koyama, H Korideck, J Hai, J Deng, YY Li, ...
JCI insight 1 (9), 2016
1242016
Genomic Landscape of Human Papillomavirus–Associated CancersGenomics of HPV-Associated Cancers
M Rusan, YY Li, PS Hammerman
Clinical cancer research 21 (9), 2009-2019, 2015
1142015
Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers
J Laskin, S Jones, S Aparicio, S Chia, C Ch'ng, R Deyell, P Eirew, A Fok, ...
Molecular Case Studies 1 (1), a000570, 2015
1082015
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung CancerAn Oncogenic Role for EZH2 in Lung Cancer
H Zhang, J Qi, JM Reyes, L Li, PK Rao, F Li, CY Lin, JA Perry, MA Lawlor, ...
Cancer discovery 6 (9), 1006-1021, 2016
962016
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLCResistance Mechanisms to MET Tyrosine Kinase Inhibitors
G Recondo, M Bahcall, LF Spurr, J Che, B Ricciuti, GC Leonardi, YC Lo, ...
Clinical Cancer Research 26 (11), 2615-2625, 2020
952020
Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating anti-tumor immunity
JJ Miret, P Kirschmeier, S Koyama, M Zhu, YY Li, Y Naito, M Wu, ...
Journal for immunotherapy of cancer 7 (1), 1-12, 2019
842019
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L) 1 Immune Checkpoint Inhibition in Non–Small Cell Lung CancerDDR Gene Mutations and …
B Ricciuti, G Recondo, LF Spurr, YY Li, G Lamberti, D Venkatraman, ...
Clinical Cancer Research 26 (15), 4135-4142, 2020
772020
The system can't perform the operation now. Try again later.
Articles 1–20